Spring Bank Pharmaceuticals Inc
01748 Hopkinton, United States
Spring Bank Pharmaceuticals Inc Company Information
Vispārīga informācija
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company's lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.
86 South Street Hopkinton
- Darba laiks
-
Pirmdiena:08:30 - 17:00Otrdiena:08:30 - 17:00Trešdiena:08:30 - 17:00Ceturtdiena:08:30 - 17:00Piektdiena:08:30 - 17:00
- Autostāvvieta
- Uzņēmumam ir autostāvvieta.
- Tālruņa numurs
- +1508-473-5993
- Linki
- Sociālie konti
- Atslēgas vārdi
- farmācijas uzņēmums
Spring Bank Pharmaceuticals Inc Reviews & Ratings
How do you rate this company?
Are you the owner of this company? If so, do not lose the opportunity to update your company's profile, add products, offers and higher position in search engines.